Charité – Universitätsmedizin Berlin at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Charité – Universitätsmedizin Berlin takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on the PRImus-AD trial of the oral drug PRI-002, with topline phase 2b results in early Alzheimer's disease. Its work also covers how sample transport and comorbidities affect blood biomarker performance.

Organization	CTAD 2026 Attendance
Charité – Universitätsmedizin Berlin Berlin, Germany
	Talk Tue Nov 17 10:05am Topline results from the Phase 2b PRImus-AD trial: Safety and efficacy of oral PRI-002 in early AD Anti-amyloid and anti-tau therapies Poster Wed Nov 18 7:15am–5:30pm Influence of Pre-analytical Transport Conditions, Routine Blood Biomarkers, and Comorbidities on the performance of Elecsys plasma p-Tau181 (TAPOREWORLD study) (P239) Blood and CSF biomarkers

Instantly find 20 buyers from Charité – Universitätsmedizin Berlin

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction